WO2010126246A3 - ANTI ErbB2 RNA APTAMER AND APPLICATIONS THEREFOR - Google Patents

ANTI ErbB2 RNA APTAMER AND APPLICATIONS THEREFOR Download PDF

Info

Publication number
WO2010126246A3
WO2010126246A3 PCT/KR2010/002409 KR2010002409W WO2010126246A3 WO 2010126246 A3 WO2010126246 A3 WO 2010126246A3 KR 2010002409 W KR2010002409 W KR 2010002409W WO 2010126246 A3 WO2010126246 A3 WO 2010126246A3
Authority
WO
WIPO (PCT)
Prior art keywords
erbb2
rna aptamer
aptamer
applications therefor
expression
Prior art date
Application number
PCT/KR2010/002409
Other languages
French (fr)
Korean (ko)
Other versions
WO2010126246A2 (en
Inventor
정선주
김미영
Original Assignee
단국대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 단국대학교산학협력단 filed Critical 단국대학교산학협력단
Publication of WO2010126246A2 publication Critical patent/WO2010126246A2/en
Publication of WO2010126246A3 publication Critical patent/WO2010126246A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention relates to an anti ErbB2 RNA aptamer which has a high affinity for and binds specifically to the extracellular domain of ErbB2, and relates to applications for the aptamer as a composition for the treatment and diagnosis of relevant medical conditions which occur due to changes in ErbB2 expression or signal transmission in which ErbB2 is involved. The RNA aptamer of the present invention can be usefully applied as an in-vivo or ex-vivo tumour imaging means and an anti-tumour composition for cancers involving the over-expression of ErbB2.
PCT/KR2010/002409 2009-05-01 2010-04-19 ANTI ErbB2 RNA APTAMER AND APPLICATIONS THEREFOR WO2010126246A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0038759 2009-05-01
KR1020090038759A KR101109466B1 (en) 2009-05-01 2009-05-01 RNA Aptamer binding to ErbB2 and Use thereof

Publications (2)

Publication Number Publication Date
WO2010126246A2 WO2010126246A2 (en) 2010-11-04
WO2010126246A3 true WO2010126246A3 (en) 2011-03-10

Family

ID=43032652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/002409 WO2010126246A2 (en) 2009-05-01 2010-04-19 ANTI ErbB2 RNA APTAMER AND APPLICATIONS THEREFOR

Country Status (2)

Country Link
KR (1) KR101109466B1 (en)
WO (1) WO2010126246A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101698654B1 (en) * 2014-12-24 2017-01-20 포항공과대학교 산학협력단 DNA aptamer specifically binding to EN2 (Engrailed-2) and use thereof
KR102325731B1 (en) * 2020-01-15 2021-11-15 주식회사 베르티스 A Composition for Diagnosing Cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US7098302B2 (en) * 2001-10-12 2006-08-29 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of ErbB2 and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US7098302B2 (en) * 2001-10-12 2006-08-29 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of ErbB2 and uses therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOLBRO, T. ET AL., PNAS., vol. 100, no. 15, 22 July 2003 (2003-07-22), pages 8933 - 8938 *
KUNZ, C. ET AL., MOLECULAR CANCER RESEARCH., vol. 4, 22 December 2006 (2006-12-22), pages 983 - 998 *
PARK, E. S. ET AL., BIOCHEMISTRY, vol. 47, no. 46, 18 November 2008 (2008-11-18), pages 11992 - 12005 *

Also Published As

Publication number Publication date
KR20100119689A (en) 2010-11-10
WO2010126246A2 (en) 2010-11-04
KR101109466B1 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
AU2010230585A8 (en) Autotaxin inhibitors
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009126688A3 (en) Novel compositions and methods for the treatment of immune related diseases
MX2012004415A (en) Dual variable domain immunoglobulins and uses thereof.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012001262A (en) Dual variable domain immunoglobulins and uses thereof.
WO2009102820A3 (en) Modified sugar substrates and methods of use
WO2011106297A3 (en) Compositions and methods for the diagnosis and treatment of tumor
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
WO2013123152A3 (en) ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
IN2012DN02081A (en)
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2010140834A3 (en) Nucleic acid aptamer specifically binding to pancreatic cancer cells or tissues and use thereof
MX2012001413A (en) Novel azaheterocyclic compounds.
WO2011066503A3 (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
IN2012DN01979A (en)
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10769891

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10769891

Country of ref document: EP

Kind code of ref document: A2